{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T20:28:10Z","timestamp":1747168090229,"version":"3.40.5"},"reference-count":73,"publisher":"JLE","issue":"2","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.nephro.2018.10.003","type":"journal-article","created":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T14:02:52Z","timestamp":1549029772000},"page":"71-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Beta-blockers use from the general to the hemodialysis population"],"prefix":"10.1684","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9893-5514","authenticated-orcid":false,"given":"Mabel","family":"Aoun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2987-9568","authenticated-orcid":false,"given":"Randa","family":"Tabbah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18929","reference":[{"key":"10.1016\/j.nephro.2018.10.003_bib0370","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJM197403282901301","article-title":"Accelerated atherosclerosis in prolonged maintenance hemodialysis","volume":"290","author":"Lindner","year":"1974","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2018.10.003_bib0375","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/ndt\/gfh242","article-title":"Sympathetic hyperactivity in chronic kidney disease","volume":"19","author":"Blankestijn","year":"2004","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 3","key":"10.1016\/j.nephro.2018.10.003_bib0380","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients","volume":"45","author":"National Kidney Foundation","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2018.10.003_bib0385","first-page":"565","article-title":"Beta-adrenergic blockers: a 50-year historical perspective","volume":"15","author":"Frishman","year":"2008","journal-title":"Am J Ther"},{"key":"10.1016\/j.nephro.2018.10.003_bib0390","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1136\/hrt.36.11.1109","article-title":"Apex cardiogram and systolic time intervals in acute myocardial infarction and effect of practolol","volume":"36","author":"Waagstein","year":"1974","journal-title":"Br Heart J"},{"key":"10.1016\/j.nephro.2018.10.003_bib0395","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0954-6111(03)00168-9","article-title":"Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis","volume":"97","author":"Salpeter","year":"2003","journal-title":"Respir Med"},{"key":"10.1016\/j.nephro.2018.10.003_bib0400","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1345\/aph.1D113","article-title":"Use of beta-blockers in patients with COPD","volume":"38","author":"Andrus","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.nephro.2018.10.003_bib0405","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0140-6736(81)91101-6","article-title":"Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial","volume":"2","author":"Hjalmarson","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2018.10.003_bib0410","doi-asserted-by":"crossref","first-page":"11E","DOI":"10.1016\/S0002-9149(84)80305-7","article-title":"Early intervention with a beta-blocking drug after acute myocardial infarction","volume":"54","author":"Hjalmarson","year":"1984","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.nephro.2018.10.003_bib0415","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0140-6736(84)90651-2","article-title":"Prevention of ventricular fibrillation during acute myocardial infarction by intravenous propranolol","volume":"2","author":"Norris","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2018.10.003_bib0420","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJM198303173081102","article-title":"A double-blind trial of metoprolol in acute myocardial infarction effects on ventricular tachyarrhythmias","volume":"308","author":"Ryd\u00e9n","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2018.10.003_bib0425","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1097\/00004872-199306003-00013","article-title":"Primary and secondary prevention of myocardial infarction and strokes. An update of randomly allocated controlled trials","volume":"11","author":"Yusuf","year":"1993","journal-title":"J Hypertens"},{"key":"10.1016\/j.nephro.2018.10.003_bib0430","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1752-8062.2009.00163.x","article-title":"Divergent effects of losartan and metoprolol on cardiac remodeling C-kit+ cells, proliferation and apoptosis in the left ventricle after myocardial infarction","volume":"2","author":"Serpi","year":"2009","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.nephro.2018.10.003_bib0435","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0195-668X(02)00618-8","article-title":"Management of acute myocardial infarction in patients presenting with ST-segment elevation. The task force of the management of acute myocardial infarction of the European Society of Cardiology","volume":"24","author":"Van de Werf","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nephro.2018.10.003_bib0440","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/eurheartj\/ehv316","volume":"36","author":"Priori","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nephro.2018.10.003_bib0445","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1136\/bmj.318.7200.1730","article-title":"Beta blockade after myocardial infarction: systematic review and meta regression analysis","volume":"318","author":"Freemantle","year":"1999","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.nephro.2018.10.003_bib0450","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nephro.2018.10.003_bib0455","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0002-9149(90)90831-K","article-title":"Secondary prevention after high-risk acute myocardial infarction with low dose acebutolol","volume":"66","author":"Boissel","year":"1990","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.nephro.2018.10.003_bib0460","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1161\/01.CIR.0000108928.25690.94","article-title":"Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN Echo Substudy","volume":"109","author":"Doughty","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.nephro.2018.10.003_bib0465","first-page":"831","volume":"17","author":"Roffi","year":"2016","journal-title":"G Ital Cardiol (Rome)"},{"key":"10.1016\/j.nephro.2018.10.003_bib0470","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nephro.2018.10.003_bib0475","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jacc.2016.05.011","volume":"68","author":"Yancy","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.nephro.2018.10.003_bib0480","doi-asserted-by":"crossref","first-page":"e90555","DOI":"10.1371\/journal.pone.0090555","article-title":"Effects of beta-blockers on heart failure with preserved ejection fraction: a meta-analysis","volume":"9","author":"Liu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.nephro.2018.10.003_bib0485","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jacc.2003.08.013","volume":"42","author":"Blomstrom-Lundqvist","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.nephro.2018.10.003_bib0490","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/S0140-6736(65)92340-8","article-title":"Effect of adrenergic receptor blockade on the tachycardia of thyrotoxicosis and anxiety state","volume":"2","author":"Turner","year":"1965","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2018.10.003_bib0495","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1161\/01.CIR.93.6.1262","article-title":"Management of patients with atrial fibrillation. A statement for healthcare professionals. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association","volume":"93","author":"Prystowsky","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.nephro.2018.10.003_bib0500","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0195-0668X(02)00809-6","article-title":"Update of the guidelines on sudden cardiac death of the European Society of Cardiology","volume":"24","author":"Priori","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nephro.2018.10.003_bib0505","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1053\/euhj.2001.2782","article-title":"Diagnosis and management of aortic dissection","volume":"22","author":"Erbel","year":"2001","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nephro.2018.10.003_bib0510","doi-asserted-by":"crossref","first-page":"85","DOI":"10.5694\/mja16.00526","article-title":"Guideline for the diagnosis and management of hypertension in adults","volume":"205","author":"Gabb","year":"2016","journal-title":"Med J Aust"},{"key":"10.1016\/j.nephro.2018.10.003_bib0515","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.nephro.2018.10.003_bib0520","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.ehj.2004.06.002","article-title":"Expert consensus document on beta-adrenergic receptor blockers","volume":"25","author":"L\u00f3pez-Send\u00f3n","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nephro.2018.10.003_bib0525","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/0002-9149(83)90113-3","article-title":"Detrimental effect of propranolol in patients with coronary arterial spasm countered by combination with diltiazem","volume":"52","author":"Tilmant","year":"1983","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.nephro.2018.10.003_bib0530","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJM197911153012003","article-title":"Ventricular fibrillation in the Wolff\u2013Parkinson-White syndrome","volume":"301","author":"Klein","year":"1979","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2018.10.003_bib0535","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/ehf2.12055","article-title":"Heart failure, chronic obstructive pulmonary disease, and asthma: numbers, facts, and challenges","volume":"2","author":"Lainscak","year":"2015","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.nephro.2018.10.003_bib0540","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1053\/j.ajkd.2015.10.029","article-title":"The \u03b2-Blocker to lower cardiovascular dialysis events (BLOCADE) feasibility study: a randomized controlled trial","volume":"67","author":"Roberts","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2018.10.003_bib0545","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/0886022X.2012.745119","article-title":"Pharmacologic treatment in dialysis patients hospitalized for cardiovascular reasons: Do we follow the guidelines?","volume":"35","author":"Tomaszuk-Kazberuk","year":"2012","journal-title":"Ren Fail"},{"key":"10.1016\/j.nephro.2018.10.003_bib0550","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1681\/ASN.2013060632","article-title":"Evidence-based cardiology in hemodialysis patients","volume":"24","author":"Allon","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2018.10.003_bib0555","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0828-282X(06)70291-4","article-title":"Cardioprotective medication use in hemodialysis patients","volume":"22","author":"Miller","year":"2006","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.nephro.2018.10.003_bib0560","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0735-1097(03)00572-2","article-title":"Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction","volume":"42","author":"Berger","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.nephro.2018.10.003_bib0565","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1046\/j.1523-1755.2002.00636.x","article-title":"Blood pressure and long-term mortality in United States hemodialysis patients: USRDS waves 3 and 4 study","volume":"62","author":"Foley","year":"2002","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2018.10.003_bib0570","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/ndt\/gft515","article-title":"Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial","volume":"29","author":"Agarwal","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2018.10.003_bib0575","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1093\/ndt\/gfr460","article-title":"Beta-blockers and cardiovascular outcomes in dialysis patients: a cohort study in Ontario, Canada","volume":"27","author":"Kitchlu","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2018.10.003_bib0580","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12872-016-0233-3","article-title":"Effectiveness comparison of cardio-selective to non-selective \u03b2-blockers and their association with mortality and morbidity in end-stage renal disease: a retrospective cohort study","volume":"16","author":"Shireman","year":"2016","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.nephro.2018.10.003_bib0585","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S0735-1097(03)00241-9","article-title":"Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial","volume":"41","author":"Cice","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.nephro.2018.10.003_bib0590","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/sdi.12093","article-title":"Sympathetic nervous system function and dysfunction in chronic hemodialysis patients","volume":"26","author":"Rubinger","year":"2013","journal-title":"Semin Dial"},{"key":"10.1016\/j.nephro.2018.10.003_bib0595","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.autneu.2016.11.002","article-title":"Potential role of endurance training in altering renal sympathetic nerve activity in CKD","volume":"204","author":"Howden","year":"2017","journal-title":"Auton Neurosci"},{"key":"10.1016\/j.nephro.2018.10.003_bib0600","first-page":"191","article-title":"Cardiac autonomic dysfunction in hemodialysis patients assessed by heart rate variability","volume":"64","author":"Christensen","year":"2012","journal-title":"Minerva Urol Nefrol"},{"key":"10.1016\/j.nephro.2018.10.003_bib0605","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/ndt\/gfm634","article-title":"Heart rate variability (HRV) in kidney failure: measurement and consequences of reduced HRV","volume":"23","author":"Ranpuria","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2018.10.003_bib0610","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"German diabetes and dialysis study investigators: atorvastatin in patients with type\u00a02 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"year":"2006","series-title":"US Renal Data System 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States","author":"United States Renal Data System","key":"10.1016\/j.nephro.2018.10.003_bib0615"},{"issue":"2","key":"10.1016\/j.nephro.2018.10.003_bib0620","doi-asserted-by":"crossref","first-page":"155","DOI":"10.5935\/0101-2800.20140025","article-title":"Depressed cardiac autonomic modulation in patients with chronic kidney disease","volume":"36","author":"De Oliveira","year":"2014","journal-title":"J Bras Nefrol"},{"key":"10.1016\/j.nephro.2018.10.003_bib0625","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00198-014-2862-7","article-title":"Plasma FGF23 levels and heart rate variability in patients with stage 5 CKD","volume":"26","author":"Zhang","year":"2015","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.nephro.2018.10.003_bib0630","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2369-15-26","article-title":"Effects of fluid overload on heart rate variability in chronic kidney disease patients on hemodialysis","volume":"15","author":"Ferrario","year":"2014","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.nephro.2018.10.003_bib0635","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1093\/ndt\/gfq234","article-title":"Abnormal nocturnal heart rate variability response among chronic kidney disease and dialysis patients during wakefulness and sleep","volume":"25","author":"Roumelioti","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2018.10.003_bib0640","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2215\/CJN.02360706","article-title":"Predictors of survival after cardiac arrest in outpatient hemodialysis clinics","volume":"2","author":"Pun","year":"2007","journal-title":"CJASN"},{"key":"10.1016\/j.nephro.2018.10.003_bib0645","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1038\/sj.ki.5000446","article-title":"SCD due to CAD and therapeutic target beta-blocker","volume":"69","author":"Bleyer","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2018.10.003_bib0650","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ijcard.2011.09.037","article-title":"\u03b2-blocker prevents sudden cardiac death in patients with hemodialysis","volume":"165","author":"Matsue","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.nephro.2018.10.003_bib0655","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jacc.2014.12.049","article-title":"Bradycardia and asystole is the predominant mechanisma of sudden cardiac death in patients with chronic kidney disease","volume":"65","author":"Wong","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.nephro.2018.10.003_bib0660","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.kint.2017.11.019","article-title":"Primary outcomes of the monitoring in dialysis study indicate that clinically significant arrhythmias are common in hemodialysis patients and related to dialytic cycle","volume":"93","author":"Roy-Chaudhury","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2018.10.003_bib0665","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/ki.2009.185","article-title":"Atrial fibrillation in incident dialysis patients","volume":"76","author":"Vazquez","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2018.10.003_bib0670","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/europace\/eur023","article-title":"Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part\u00a0II: secondary prevention","volume":"13","author":"Savelieva","year":"2011","journal-title":"Europace"},{"key":"10.1016\/j.nephro.2018.10.003_bib0675","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/ndt\/15.6.765","article-title":"Atrial fibrillation in dialysis patients","volume":"15","author":"Zebe","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2018.10.003_bib0680","doi-asserted-by":"crossref","first-page":"17731","DOI":"10.1038\/srep17731","article-title":"Primary prevention of atrial fibrillation with beta-blockers in patients with end-stage renal disease undergoing dialysis","volume":"5","author":"Lin","year":"2015","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.nephro.2018.10.003_bib0685","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1053\/j.ajkd.2018.02.350","article-title":"A comparative study of carvedilol versus metoprolol initiation and 1-year mortality among individuals receiving maintenance hemodialysis","volume":"72","author":"Assimon","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2018.10.003_bib0690","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/ki.1995.132","article-title":"Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors","volume":"47","author":"Harnett","year":"1995","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.nephro.2018.10.003_bib0695","doi-asserted-by":"crossref","first-page":"e002584","DOI":"10.1161\/JAHA.115.002584","article-title":"Prognostic benefits of carvedilol, bisoprolol, and metoprolol controlled release\/extended release in hemodialysis patients with heart failure: a 10-year cohort","volume":"5","author":"Tang","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.nephro.2018.10.003_bib0700","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.jacc.2011.04.041","article-title":"Effects of beta-adrenergic antagonists in patients with chronic kidney disease","volume":"58","author":"Badve","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.nephro.2018.10.003_bib0705","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1681\/ASN.2014040324","article-title":"\u03b2-Blocker dialyzability and mortality in older patients receiving hemodialysis","volume":"26","author":"Weir","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.nephro.2018.10.003_bib0710","doi-asserted-by":"crossref","first-page":"604","DOI":"10.2215\/CJN.07470717","article-title":"Beta-blocker dialyzability in maintenance hemodialysis patients: a randomized clinical trial","volume":"13","author":"Tieu","year":"2018","journal-title":"CJASN"},{"key":"10.1016\/j.nephro.2018.10.003_bib0715","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1681\/ASN.V10122577","article-title":"Hemodynamic patterns and spectral analysis of heart rate variability during dialysis hypotension","volume":"10","author":"Barnas","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2018.10.003_bib0720","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1042\/cs0960023","article-title":"Impaired sympathetic response before intradialytic hypotension; a study based on spectral analysis of heart rate and pressure variability","volume":"96","author":"Pelosi","year":"1999","journal-title":"Clin Sci"},{"key":"10.1016\/j.nephro.2018.10.003_bib0725","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/ndt\/12.3.519","article-title":"The heart rate response pattern to dialysis hypotension in haemodialysis patients","volume":"12","author":"Zoccali","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2018.10.003_bib0730","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1159\/000058396","article-title":"Non-selective beta-adrenergic blockade augments fasting hyperkalemia in hemodialysis patients","volume":"91","author":"Nowicki","year":"2002","journal-title":"Nephron"}],"container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725518306564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725518306564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2018.10.003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T16:20:21Z","timestamp":1741191621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725518306564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":73,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S1769725518306564"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2018.10.003","relation":{},"ISSN":["1769-7255"],"issn-type":[{"type":"print","value":"1769-7255"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beta-blockers use from the general to the hemodialysis population","name":"articletitle","label":"Article Title"},{"value":"N\u00e9phrologie & Th\u00e9rapeutique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nephro.2018.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 francophone de n\u00e9phrologie, dialyse et transplantation. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}